The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Avidity Biosciences Inc shares valued at $929,864 were purchased by ERIC MOSBROOKER on Sep 03 ’25. At $47.23 per share, ERIC MOSBROOKER acquired 19,688 shares.
Also, Gallagher Kathleen P. sold 188 shares, netting a total of over 8,915 in proceeds. Following the sale of shares at $47.42 each, the insider now holds 50,204 shares.
Before that, Boyce Sarah had sold 25,000 shares from its account. In a trade valued at $1,234,700, the President and CEO traded Avidity Biosciences Inc shares for $49.39 each. Upon closing the transaction, the insider’s holdings decreased to 25,000 shares, worth approximately $14.56 million.
Analysts at Bernstein started covering the stock with ‘”an Outperform”‘ outlook in a report released in late June. As of June 17, 2025, Wolfe Research has initiated its “an Outperform” rating for RNA. Earlier on June 11, 2025, Raymond James initiated its rating. Their recommendation was “a Strong buy” for RNA stock.
Analyzing RNA Stock Performance
On last trading session, Avidity Biosciences Inc [NASDAQ: RNA] rose 0.76% to $47.59. The stock’s lowest price that day was $45.68, but it reached a high of $48.44 in the same session. During the last five days, there has been a surge of approximately 1.15%. Over the course of the year, Avidity Biosciences Inc shares have jumped approximately 11.61%. Shares of the company reached a 52-week high of $49.76 on 08/28/25 and a 52-week low of $21.51 on 04/09/25.
Support And Resistance Levels for Avidity Biosciences Inc (RNA)
According to the 24-hour chart, there is a support level at 46.03, which, if violated, would cause prices to drop to 44.48. In the upper region, resistance lies at 48.79. The next price resistance is at 50.00. RSI (Relative Strength Index) is 64.36 on the 14-day chart, showing neutral technical sentiment.
Is Avidity Biosciences Inc subject to short interest?
Stocks of Avidity Biosciences Inc saw a sharp steep in short interest on 2025-08-15 dropping by -0.59 million shares to 15.67 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 16.26 million shares. A decline of -3.75% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.31 of the overall float, the days-to-cover ratio (short ratio) decline to 4.31.
Which companies own the most shares of Avidity Biosciences Inc (RNA)?
In terms of Avidity Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 70 in the next 12 months, up nearly 48.21% from the previous closing price of $47.23. Analysts anticipate Avidity Biosciences Inc stock to reach 70 by 2025, with the lowest price target being 70. In spite of this, 6 analysts ranked Avidity Biosciences Inc stock as Buy at the end of 2025. On March 13, 2025, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $70.
